Tildrakizumab for treating psoriasis
- 10 March 2017
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Biological Therapy
- Vol. 17 (5), 645-657
- https://doi.org/10.1080/14712598.2017.1304537
Abstract
Agents that block inflammatory pathways other than tumor necrosis factor (TNF) have represented new options for treating psoriasis in recent years. IL-23 is involved in regulating Th17 cells and is a potent activator of keratinocyte proliferation. Targeting IL-23p19 alone may be a promising treatment approach in patients with moderate-to-severe chronic plaque psoriasis, with a downregulation of Th17 and Th22 cell responses, while IL-12 blockade is not required to achieve efficacy in these patients. Areas covered: The authors review and provide an update on tildrakizumab, a humanized IgG1 monoclonal antibody that blocks the p19 subunit of IL-23. Expert opinion: Total skin clearance is an important treatment goal that has both measurable and clinically meaningful benefits. Meeting patient needs about total clearance, IL-23p19 inhibitors will obtain a specific position in the crowded psoriasis market. On the other hand, PASI 75 and PASI 90 response achieved by tildrakizumab in the phase II and III trials are less than the response achieved by the IL-17A inhibitors and other p19 competitors, possibly due to a less intensive dosing regimen, although direct comparisons cannot be made without a head-to-head randomized clinical trial.Keywords
This publication has 48 references indexed in Scilit:
- A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque PsoriasisDermatology and Therapy, 2015
- Clinical improvement in psoriasis with specific targeting of interleukin-23Nature, 2015
- Efficacy and Safety of Emerging Immunotherapies in PsoriasisImmunotherapy, 2015
- Specific targeting of interleukin-23p19 as effective treatment for psoriasisJournal of the American Academy of Dermatology, 2013
- TofacitinibHospital Pharmacy, 2013
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and PrevalenceJournal of Investigative Dermatology, 2013
- Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspectiveAnnals Of The Rheumatic Diseases, 2012
- IL-23–Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17APublished by The American Association of Immunologists ,2011
- Pathogenesis and clinical features of psoriasisThe Lancet, 2007
- IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesisThe Journal of Experimental Medicine, 2006